{"id":46111,"date":"2022-07-13T12:01:57","date_gmt":"2022-07-13T10:01:57","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/u-s-alliance-pharma-acquires-u-k-based-lgcs-drug-development-solutions-dds-business\/"},"modified":"2022-07-13T12:01:57","modified_gmt":"2022-07-13T10:01:57","slug":"u-s-alliance-pharma-acquires-u-k-based-lgcs-drug-development-solutions-dds-business","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/u-s-alliance-pharma-acquires-u-k-based-lgcs-drug-development-solutions-dds-business\/","title":{"rendered":"U.S. Alliance Pharma Acquires U.K.-based LGC\u2019s Drug Development Solutions (DDS) Business"},"content":{"rendered":"
\n

\nExpands bioanalytical services to include many emerging areas worldwide<\/i>\n<\/p>\n

MALVERN, Pa.–(BUSINESS WIRE)–Alliance Pharma<\/a> (Alliance), a U.S. leader in small and large molecule bioanalytical services in the pharmaceutical and biopharmaceutical industry, today closed on the purchase of Drug Development Solutions <\/a>(DDS), a U.K.-based bioanalytical and material science testing contract research organization (CRO), from LGC<\/a>. Ampersand Capital Partners<\/a>, a global healthcare private equity firm, and KKR & Co. Inc.<\/a> (KKR) (NYSE:KKR), a leading global investment firm, are equal shareholders in the combined company. This transaction expands bioanalytical, analytical material testing and laboratory capabilities internationally for the biopharma and pharma industry, including areas of cell and gene therapy, next-generation biologics, material sciences and protein characterization.\n<\/p>\n

<\/a><\/p>\n

\n\u201cTogether, Alliance and DDS will partner with customers on a global basis to provide advanced bioanalytical and analytical material services for both large and small molecules, particularly supporting many emerging bioanalytical and analytical science areas the industry needs right now,\u201d said Alliance Chairman of the Board and a Partner at Ampersand Capital Partners Dave Patteson<\/a>. \u201cAlongside Alliance\u2019s bioanalytical expertise, DDS adds an unrivalled breadth and depth of expertise in bioanalysis and analytical and materials science as well as two state-of-the-art analytical labs in Cambridge (Fordham), U.K., and Sandwich, Kent, U.K. Their Cambridge facility is one of the largest bioanalytical centers in the world with about 270 employees.\u201d\n<\/p>\n

\nThis acquisition positions Alliance to become an international bioanalytical service provider for all therapeutic modalities.\n<\/p>\n

\nAbout Alliance Pharma<\/b>\n<\/p>\n

\nFounded in 2008, Alliance<\/a> is a contract research organization (CRO) in Malvern, PA, just outside of Philadelphia that specializes in advanced bioanalytical research services for both small and large molecule drugs, as well as drug metabolism studies to support pharmaceutical and biotechnology companies\u2019 drug discovery and development programs. Alliance\u2019s mission is to build a trusted partnership with our clients to support their successful drug development programs. Our business philosophy is based on a foundation of trust, professional ethics, scientific excellence and regulatory compliance.\n<\/p>\n

\nAbout Drug Development Solutions (An LGC Business Unit)<\/b>\n<\/p>\n

\nDDS<\/a>\u2019s Bioanalytical solutions include liquid-chromatography mass spectrometry (LC-MS) and immunoassay bioanalysis, to provide data for pharmacokinetics, immunogenicity, pharmacodynamics and cell-based assays supporting all phases of drug development to GCP and GLP standards. Its Analytical Materials Sciences solutions provides specialist testing of raw materials, formulated products, packaging and medical devices for trace impurities, contamination, degradation and quality control to support CMC (Chemistry Manufacturing and Control) analytical testing to GMP (Good Manufacturing Practice) standard.\n<\/p>\n

\nAbout Ampersand Capital Partners<\/b>\n<\/p>\n

\nFounded in 1988, Ampersand is a middle market private equity firm with more than $2 billion of assets under management dedicated to growth-oriented investments in the healthcare sector. With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm\u2019s core healthcare sectors. Additional information about Ampersand is available at ampersandcapital.com<\/a>.\n<\/p>\n

\nAbout KKR<\/b>\n<\/p>\n

\nKKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR\u2019s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR\u2019s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR\u2019s website at www.kkr.com<\/a> and on Twitter @KKR_Co<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nLindsey Langemeier
\n
SCORR Marketing
\n
402-405-4269
\n
lindsey@scorrmarketing.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Expands bioanalytical services to include many emerging areas worldwide MALVERN, Pa.–(BUSINESS WIRE)–Alliance Pharma (Alliance), a U.S. leader in small and large molecule bioanalytical services in the pharmaceutical and biopharmaceutical industry, today closed on the purchase of Drug Development Solutions (DDS), a U.K.-based bioanalytical and material science testing contract research organization (CRO), from LGC. Ampersand Capital … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46111","6":"format-standard","7":"category-industry"},"yoast_head":"\nU.S. Alliance Pharma Acquires U.K.-based LGC\u2019s Drug Development Solutions (DDS) Business - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/u-s-alliance-pharma-acquires-u-k-based-lgcs-drug-development-solutions-dds-business\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"U.S. Alliance Pharma Acquires U.K.-based LGC\u2019s Drug Development Solutions (DDS) Business - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Expands bioanalytical services to include many emerging areas worldwide MALVERN, Pa.–(BUSINESS WIRE)–Alliance Pharma (Alliance), a U.S. leader in small and large molecule bioanalytical services in the pharmaceutical and biopharmaceutical industry, today closed on the purchase of Drug Development Solutions (DDS), a U.K.-based bioanalytical and material science testing contract research organization (CRO), from LGC. Ampersand Capital ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/u-s-alliance-pharma-acquires-u-k-based-lgcs-drug-development-solutions-dds-business\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-13T10:01:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220713005250\/en\/1511992\/21\/Alliance_Pharma-Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-alliance-pharma-acquires-u-k-based-lgcs-drug-development-solutions-dds-business\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-alliance-pharma-acquires-u-k-based-lgcs-drug-development-solutions-dds-business\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"U.S. Alliance Pharma Acquires U.K.-based LGC\u2019s Drug Development Solutions (DDS) Business\",\"datePublished\":\"2022-07-13T10:01:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-alliance-pharma-acquires-u-k-based-lgcs-drug-development-solutions-dds-business\\\/\"},\"wordCount\":649,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-alliance-pharma-acquires-u-k-based-lgcs-drug-development-solutions-dds-business\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220713005250\\\/en\\\/1511992\\\/21\\\/Alliance_Pharma-Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-alliance-pharma-acquires-u-k-based-lgcs-drug-development-solutions-dds-business\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-alliance-pharma-acquires-u-k-based-lgcs-drug-development-solutions-dds-business\\\/\",\"name\":\"U.S. Alliance Pharma Acquires U.K.-based LGC\u2019s Drug Development Solutions (DDS) Business - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-alliance-pharma-acquires-u-k-based-lgcs-drug-development-solutions-dds-business\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-alliance-pharma-acquires-u-k-based-lgcs-drug-development-solutions-dds-business\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220713005250\\\/en\\\/1511992\\\/21\\\/Alliance_Pharma-Logo.jpg\",\"datePublished\":\"2022-07-13T10:01:57+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-alliance-pharma-acquires-u-k-based-lgcs-drug-development-solutions-dds-business\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-alliance-pharma-acquires-u-k-based-lgcs-drug-development-solutions-dds-business\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-alliance-pharma-acquires-u-k-based-lgcs-drug-development-solutions-dds-business\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220713005250\\\/en\\\/1511992\\\/21\\\/Alliance_Pharma-Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220713005250\\\/en\\\/1511992\\\/21\\\/Alliance_Pharma-Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-alliance-pharma-acquires-u-k-based-lgcs-drug-development-solutions-dds-business\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"U.S. Alliance Pharma Acquires U.K.-based LGC\u2019s Drug Development Solutions (DDS) Business\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"U.S. Alliance Pharma Acquires U.K.-based LGC\u2019s Drug Development Solutions (DDS) Business - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/u-s-alliance-pharma-acquires-u-k-based-lgcs-drug-development-solutions-dds-business\/","og_locale":"en_US","og_type":"article","og_title":"U.S. Alliance Pharma Acquires U.K.-based LGC\u2019s Drug Development Solutions (DDS) Business - Pharma Trend","og_description":"Expands bioanalytical services to include many emerging areas worldwide MALVERN, Pa.–(BUSINESS WIRE)–Alliance Pharma (Alliance), a U.S. leader in small and large molecule bioanalytical services in the pharmaceutical and biopharmaceutical industry, today closed on the purchase of Drug Development Solutions (DDS), a U.K.-based bioanalytical and material science testing contract research organization (CRO), from LGC. Ampersand Capital ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/u-s-alliance-pharma-acquires-u-k-based-lgcs-drug-development-solutions-dds-business\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-13T10:01:57+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220713005250\/en\/1511992\/21\/Alliance_Pharma-Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/u-s-alliance-pharma-acquires-u-k-based-lgcs-drug-development-solutions-dds-business\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/u-s-alliance-pharma-acquires-u-k-based-lgcs-drug-development-solutions-dds-business\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"U.S. Alliance Pharma Acquires U.K.-based LGC\u2019s Drug Development Solutions (DDS) Business","datePublished":"2022-07-13T10:01:57+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/u-s-alliance-pharma-acquires-u-k-based-lgcs-drug-development-solutions-dds-business\/"},"wordCount":649,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/u-s-alliance-pharma-acquires-u-k-based-lgcs-drug-development-solutions-dds-business\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220713005250\/en\/1511992\/21\/Alliance_Pharma-Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/u-s-alliance-pharma-acquires-u-k-based-lgcs-drug-development-solutions-dds-business\/","url":"https:\/\/pharma-trend.com\/en\/u-s-alliance-pharma-acquires-u-k-based-lgcs-drug-development-solutions-dds-business\/","name":"U.S. Alliance Pharma Acquires U.K.-based LGC\u2019s Drug Development Solutions (DDS) Business - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/u-s-alliance-pharma-acquires-u-k-based-lgcs-drug-development-solutions-dds-business\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/u-s-alliance-pharma-acquires-u-k-based-lgcs-drug-development-solutions-dds-business\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220713005250\/en\/1511992\/21\/Alliance_Pharma-Logo.jpg","datePublished":"2022-07-13T10:01:57+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/u-s-alliance-pharma-acquires-u-k-based-lgcs-drug-development-solutions-dds-business\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/u-s-alliance-pharma-acquires-u-k-based-lgcs-drug-development-solutions-dds-business\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/u-s-alliance-pharma-acquires-u-k-based-lgcs-drug-development-solutions-dds-business\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220713005250\/en\/1511992\/21\/Alliance_Pharma-Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220713005250\/en\/1511992\/21\/Alliance_Pharma-Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/u-s-alliance-pharma-acquires-u-k-based-lgcs-drug-development-solutions-dds-business\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"U.S. Alliance Pharma Acquires U.K.-based LGC\u2019s Drug Development Solutions (DDS) Business"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46111","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46111"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46111\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46111"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46111"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46111"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}